Abstract
Background: In today’s context when liver diseases have spread across countries and people of all ages, it is of high importance to consider novel methods of non-toxic and long lived therapeutics. Among various therapies, immunotherapy for acute and chronic liver diseases is rapidly moving to the forefront among treatment options in hepatology medicine.
Objective: The present review covers the recent advances in immunotherapy of hepatocellular carcinoma (HCC), viral hepatitis, cirrhosis, obesity induced inflammation, non alcoholic fatty liver diseases (NAFLD), and drug induced liver injury (DILI) and disease pertaining to autoimmunity in liver. Methods: A Literature search pertaining to liver immune tolerance and various immunotherapies using the major scientific databases on preclinical studies as well as clinical trials and meta-analysis were analyzed to know about the tolerance and immunotherapy of liver diseases. Results: Immunotherapy in liver might be problematic owing to the immune tolerance property of liver. The key to therapeutic approach by utilizing this immune biology of liver is based on harnessing the immunomodulatory techniques to achieve immune activity or inhibition. Therefore, it is a necessity to overcome this immune tolerance for effective immunotherapeutic strategies. Immunotherapy may also help to boost and enhance the immunity of patients against liver diseases in combination with conventional treatment methods, or more than one method in immunotherapy may produce synergistic effect and prove to be better than when applied alone. Conclusion: Liver has a unique immuno- biological advantage which is utilized to maintain a balance between immunity and tolerance. This intricate balance of hepatic immune cells can be modulated to effect treatments in various liver diseases. However it is important to maintain a balance between the immunity of the liver and its modulation to provide protection against hepatic disease. The key to successful curing of these conditions lies along this fine line of manipulating liver immune cells for our own benefit.Keywords: Alcoholic liver disease, DILI, HCC, immunotherapy, liver diseases, NAFLD.
Graphical Abstract
Current Drug Metabolism
Title:Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Volume: 17 Issue: 10
Author(s): Alaknanda Mishra, Pramod K. Upadhyay and Perumal Nagarajan
Affiliation:
Keywords: Alcoholic liver disease, DILI, HCC, immunotherapy, liver diseases, NAFLD.
Abstract: Background: In today’s context when liver diseases have spread across countries and people of all ages, it is of high importance to consider novel methods of non-toxic and long lived therapeutics. Among various therapies, immunotherapy for acute and chronic liver diseases is rapidly moving to the forefront among treatment options in hepatology medicine.
Objective: The present review covers the recent advances in immunotherapy of hepatocellular carcinoma (HCC), viral hepatitis, cirrhosis, obesity induced inflammation, non alcoholic fatty liver diseases (NAFLD), and drug induced liver injury (DILI) and disease pertaining to autoimmunity in liver. Methods: A Literature search pertaining to liver immune tolerance and various immunotherapies using the major scientific databases on preclinical studies as well as clinical trials and meta-analysis were analyzed to know about the tolerance and immunotherapy of liver diseases. Results: Immunotherapy in liver might be problematic owing to the immune tolerance property of liver. The key to therapeutic approach by utilizing this immune biology of liver is based on harnessing the immunomodulatory techniques to achieve immune activity or inhibition. Therefore, it is a necessity to overcome this immune tolerance for effective immunotherapeutic strategies. Immunotherapy may also help to boost and enhance the immunity of patients against liver diseases in combination with conventional treatment methods, or more than one method in immunotherapy may produce synergistic effect and prove to be better than when applied alone. Conclusion: Liver has a unique immuno- biological advantage which is utilized to maintain a balance between immunity and tolerance. This intricate balance of hepatic immune cells can be modulated to effect treatments in various liver diseases. However it is important to maintain a balance between the immunity of the liver and its modulation to provide protection against hepatic disease. The key to successful curing of these conditions lies along this fine line of manipulating liver immune cells for our own benefit.Export Options
About this article
Cite this article as:
Mishra Alaknanda, Upadhyay K. Pramod and Nagarajan Perumal, Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance, Current Drug Metabolism 2016; 17 (10) . https://dx.doi.org/10.2174/1389200218666161116120301
DOI https://dx.doi.org/10.2174/1389200218666161116120301 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies
Current Pharmaceutical Biotechnology The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Serum Vitamin E (α-Tocopherol) Estimation: A Potential Biomarker of Antioxidant Status Evaluation on Heavy Metal Toxicities
Recent Patents on Biomarkers Design of NAALADase Inhibitors A Novel Neuroprotective Strategy
Current Medicinal Chemistry Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Hereditary Haemorrhagic Telangiectasia: A Rare Disease As A Model for the Study of Human Atherosclerosis
Current Pharmaceutical Design Apoptosis: A Potential Therapeutic Target for Retinal Degenerations
Current Neurovascular Research Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Multifunctional RNase MCPIP1 and its Role in Cardiovascular Diseases
Current Medicinal Chemistry The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Natural Therapies of the Inflammatory Bowel Disease: The Case of Rutin and its Aglycone, Quercetin
Mini-Reviews in Medicinal Chemistry Stem Cells and Cardiac Disease: Where are We Going?
Current Stem Cell Research & Therapy Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17
Current Alzheimer Research